John A.  Borgeson net worth and biography

John Borgeson Biography and Net Worth

Insider of Kodiak Sciences
John Borgeson is our Senior Vice President and Chief Financial Officer and has served in this position since January 2016.  From January 2013 until December 2015, Mr. Borgeson led finance for a variety of private biotech companies, including Labrys Biologics, Inc., which was acquired by Teva Pharmaceuticals.   Previously, Mr. Borgeson was a Vice President of Finance at Pfizer Inc. and a member of Pfizer’s Global Finance and Business Operations Leadership Team.  Mr. Borgeson’s roles at Pfizer included finance head for Pfizer’s biotherapeutics and bioinnovation group and corporate tax executive with responsibility for the United States and Europe.  Under Mr. Borgeson’s leadership, Pfizer completed a transformational restructuring of the global tax group that was replicated by other Fortune 50 companies.  Mr. Borgeson started his career as an auditor with Ernst & Young and is a certified public accountant (inactive).  He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.)

What is John A. Borgeson's net worth?

The estimated net worth of John A. Borgeson is at least $1.58 million as of June 17th, 2024. Mr. Borgeson owns 182,164 shares of Kodiak Sciences stock worth more than $1,575,719 as of December 22nd. This net worth estimate does not reflect any other investments that Mr. Borgeson may own. Additionally, Mr. Borgeson receives a salary of $667,520.00 as Insider at Kodiak Sciences. Learn More about John A. Borgeson's net worth.

How old is John A. Borgeson?

Mr. Borgeson is currently 62 years old. There are 2 older executives and no younger executives at Kodiak Sciences. Learn More on John A. Borgeson's age.

What is John A. Borgeson's salary?

As the Insider of Kodiak Sciences Inc., Mr. Borgeson earns $667,520.00 per year. The highest earning executive at Kodiak Sciences is Dr. Victor Perlroth M.D., Co-Founder, Chairman, CEO & President, who commands a salary of $1,080,000.00 per year. Learn More on John A. Borgeson's salary.

How do I contact John A. Borgeson?

The corporate mailing address for Mr. Borgeson and other Kodiak Sciences executives is 2631 HANOVER STREET, PALO ALTO CA, 94304. Kodiak Sciences can also be reached via phone at (650) 281-0850 and via email at [email protected]. Learn More on John A. Borgeson's contact information.

Has John A. Borgeson been buying or selling shares of Kodiak Sciences?

John A. Borgeson has not been actively trading shares of Kodiak Sciences during the past quarter. Most recently, John A. Borgeson sold 2,874 shares of the business's stock in a transaction on Monday, June 17th. The shares were sold at an average price of $2.75, for a transaction totalling $7,903.50. Following the completion of the sale, the insider now directly owns 182,164 shares of the company's stock, valued at $500,951. Learn More on John A. Borgeson's trading history.

Who are Kodiak Sciences' active insiders?

Kodiak Sciences' insider roster includes John Borgeson (Insider), and Jason Ehrlich (Insider). Learn More on Kodiak Sciences' active insiders.

Are insiders buying or selling shares of Kodiak Sciences?

In the last year, insiders at the sold shares 2 times. They sold a total of 4,432 shares worth more than $12,452.86. The most recent insider tranaction occured on June, 17th when insider John A Borgeson sold 2,874 shares worth more than $7,903.50. Insiders at Kodiak Sciences own 45.3% of the company. Learn More about insider trades at Kodiak Sciences.

Information on this page was last updated on 6/17/2024.

John A. Borgeson Insider Trading History at Kodiak Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/17/2024Sell2,874$2.75$7,903.50182,164View SEC Filing Icon  
6/12/2024Sell1,558$2.92$4,549.36179,544View SEC Filing Icon  
11/10/2021Sell876$115.42$101,107.92View SEC Filing Icon  
See Full Table

John A. Borgeson Buying and Selling Activity at Kodiak Sciences

This chart shows John A Borgeson's buying and selling at Kodiak Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kodiak Sciences Company Overview

Kodiak Sciences logo
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Read More

Today's Range

Now: $8.65
Low: $8.33
High: $8.95

50 Day Range

MA: $5.81
Low: $2.88
High: $10.15

2 Week Range

Now: $8.65
Low: $2.18
High: $11.60

Volume

355,187 shs

Average Volume

478,609 shs

Market Capitalization

$455.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.38